Improving effectiveness in communicating risk to patients

Consultant Pharmacist

Volumn 23, Issue 1, 2008, Pages 37-43

  Burkiewicz, Jill S ^a   Vesta, Kimi S ^b   Hume, Anne L ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Counseling; Elderly; Evidence based medicine; Evidence based practice; Older adults; Patient communication; Patient centered practice; Risk communication

Indexed keywords

CAREGIVER; DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE; INTERPERSONAL COMMUNICATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT COUNSELING; PHARMACIST; PHARMACY; PROFESSIONAL PRACTICE; REVIEW; RISK; RISK BENEFIT ANALYSIS;

EID: 38349122238     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2008.37     Document Type: Review

References (39)

1. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992;268:2420-5.
2. Belcher VN, Fried TR, Agostini JV et al. Views of older adults on patient participation in medication-related decision making. J Gen Intern Med 2006;21:298-303.
3. Hawker GA, Katz JN, Solomon DH. The patient's perspective on the recall of Vioxx. J Rheumatol 2006;33:1082-8.
4. Woloshin S, Schwartz LM. Media reporting on research presented at scientific meetings: more caution needed. Med J Aust 2006;184:576-80.
5. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
6. FDA News. FDA Issues Safety Alert on Avandia. Rockville, MD: United States Food and Drug Administration; May 21, 2007. http://www.fda.gov/bbs/ topics/NEWS/2007/NEW01636.html. Accessed June 11, 2007.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
8. Schwartz L, Woloshin S, Baczek L. Media coverage of scientific meetings: too much, too soon? JAMA 2002;287:2859-63.
9. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006;295:2270-4.
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
11. Levens E, Williams RS. Current opinions and understandings of menopausal women about hormone replacement therapy (HRT) - The University of Florida experience. Am J Obstet Gynecol 2004;191:641-7.
12. Ettinger B, Grady D, Tosteson ANA et al. Effect of Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
13. Lockwood S. "Evidence of me" in evidence based medicine? BMJ 2004;329:1033-5.
14. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004;291:2359-66.
15. Paling J. Strategies to help patients understand risks. BMJ 2003;327:745-8.
16. Woloshin S, Schwartz LM, Ellner A. Making sense of risk information on the web. BMJ 2003;327:695-6.
17. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002;324:827-30.
18. Knapp P, Raynor DK, Berry DC. Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Health Care 2004;13:176-80.
19. Timmermans DR. What clinicians can offer: assessing and communicating probabilities for individual patient decision making. Horm Res 1999;51 Suppl 1:58-66.
20. Trevena LJ, Davey HM, Barratt A et al. A systematic review on communicating with patients about evidence. J Eval Clin Pract 2006;12:13-23.
21. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl: 429-56.
22. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
23. Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003;138:831-8.
24. Ghosh AK, Ghosh K. Translating evidence-based information into effective risk communication: current challenges and opportunities. J Lab Clin Med 2005;145:171-80.
25. Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Making 2001;21:37-44.
26. Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ 2003;327:741-4.
27. Mayne TJ, Whalen E. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol 2006;59:217-23.
28. Goldman RE, Parker DR, Eaton CB. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006;4:205-12.
29. McAlister FA, Straus SE, Guyatt GH et al. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000;283:2829-36.
30. Peters E, Hibbard J, Slovic P et al. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Affairs 2007;26:741-8.
31. Fortin JM, Hirota LK, Bond BE et al. Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decis Mak 2001;1:2.
32. Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr 1999:149-63.
33. Cohen JT, Neumann PJ. What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Affairs 2007;26:636-46.
34. National Safety Council. What are the odds of dying? Available at http://www.nsc.org/lrs/statinfo/odds.htm. Accessed July 24, 2006.
35. Institute of Medicine. Health Literacy: A Prescription to End Confusion. Washington, DC: National Academies Press; March 2004.
36. Andrus MR, Roth MT. Health literacy: a review. Pharmacotherapy 2002;22:282-302.
37. Ad Hoc Committee on Health Literacy; American Medical Association Council on Scientific Affairs. Health literacy: report of the Council on Scientific Affairs. JAMA 1999;281:552-7.
38. Paasche-Orlow MK, Parker RM, Gazmararian JA et al. The prevalence of limited health literacy. J Gen Intern Med 2005;20:175-84.
39. Searight HR, Gafford J. Cultural diversity at the end of life: issues and guidelines for family physicians. Am Fam Physician 2005;71:515-22.